FI4426270T3 - Lipidi-nanopartikkelit oligonukleotidien kuljetusta varten - Google Patents

Lipidi-nanopartikkelit oligonukleotidien kuljetusta varten

Info

Publication number
FI4426270T3
FI4426270T3 FIEP22813505.9T FI22813505T FI4426270T3 FI 4426270 T3 FI4426270 T3 FI 4426270T3 FI 22813505 T FI22813505 T FI 22813505T FI 4426270 T3 FI4426270 T3 FI 4426270T3
Authority
FI
Finland
Prior art keywords
bis
diyl
ethyl
tetrakis
oxy
Prior art date
Application number
FIEP22813505.9T
Other languages
English (en)
Finnish (fi)
Inventor
Akm Haque
Sophie Valembois
Cafferty Séan Mc
Itishri Sahu
Christiaan Cardon
Original Assignee
Ziphius Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ziphius Nv filed Critical Ziphius Nv
Application granted granted Critical
Publication of FI4426270T3 publication Critical patent/FI4426270T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP22813505.9T 2021-11-02 2022-11-02 Lipidi-nanopartikkelit oligonukleotidien kuljetusta varten FI4426270T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21205904 2021-11-02
EP22179399 2022-06-16
PCT/EP2022/080581 WO2023078950A1 (en) 2021-11-02 2022-11-02 Lipid nanoparticles for oligonucleotide delivery

Publications (1)

Publication Number Publication Date
FI4426270T3 true FI4426270T3 (fi) 2025-09-12

Family

ID=84364268

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP22813505.9T FI4426270T3 (fi) 2021-11-02 2022-11-02 Lipidi-nanopartikkelit oligonukleotidien kuljetusta varten

Country Status (14)

Country Link
US (1) US20250236599A1 (cg-RX-API-DMAC7.html)
EP (2) EP4426270B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024540108A (cg-RX-API-DMAC7.html)
KR (1) KR20240099377A (cg-RX-API-DMAC7.html)
AU (1) AU2022381463A1 (cg-RX-API-DMAC7.html)
CA (1) CA3236653A1 (cg-RX-API-DMAC7.html)
DK (1) DK4426270T3 (cg-RX-API-DMAC7.html)
ES (1) ES3042660T3 (cg-RX-API-DMAC7.html)
FI (1) FI4426270T3 (cg-RX-API-DMAC7.html)
IL (1) IL312432B2 (cg-RX-API-DMAC7.html)
MX (1) MX2024005109A (cg-RX-API-DMAC7.html)
PL (1) PL4426270T3 (cg-RX-API-DMAC7.html)
WO (1) WO2023078950A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202403360B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
JP2025538515A (ja) * 2022-11-25 2025-11-28 艾斯拓康医薬科技(北京)有限公司 イオン化脂質及びその応用
JP2025534494A (ja) * 2022-12-23 2025-10-15 グリーン・クロス・コーポレイション イオン化可能な脂質及びその使用
CN119219539A (zh) * 2023-06-29 2024-12-31 艾斯拓康医药科技(北京)有限公司 可离子化脂质及其应用
WO2025088152A1 (en) 2023-10-27 2025-05-01 Ziphius Nv MODIFIED 5'UTRs
US12599560B2 (en) 2023-11-02 2026-04-14 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
AU2024381228A1 (en) 2023-11-13 2026-05-28 Ziphius Nv MODIFIED ALPHAVIRAL nsP3
WO2025128696A1 (en) * 2023-12-12 2025-06-19 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025255534A1 (en) * 2024-06-07 2025-12-11 Innovac Therapeutics Hk Limited Diol-based novel ionizable lipids and their uses thereof
WO2026112559A1 (en) * 2024-11-25 2026-05-28 Genzyme Corporation Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2026117525A1 (en) * 2024-11-26 2026-06-04 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
US7332322B2 (en) 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
WO2014028487A1 (en) * 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
CA2953341C (en) * 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
KR20190093816A (ko) * 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
EP3638678B1 (en) * 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents

Also Published As

Publication number Publication date
IL312432B1 (en) 2026-01-01
PL4426270T3 (pl) 2025-11-24
EP4426270B1 (en) 2025-07-23
IL312432B2 (en) 2026-05-01
EP4613741A2 (en) 2025-09-10
WO2023078950A1 (en) 2023-05-11
EP4613741A3 (en) 2025-11-12
CA3236653A1 (en) 2023-05-11
ZA202403360B (en) 2025-08-27
US20250236599A1 (en) 2025-07-24
JP2024540108A (ja) 2024-10-31
IL312432A (en) 2024-06-01
ES3042660T3 (en) 2025-11-24
KR20240099377A (ko) 2024-06-28
MX2024005109A (es) 2024-05-31
DK4426270T3 (da) 2025-09-22
EP4426270A1 (en) 2024-09-11
AU2022381463A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
JP2024540108A5 (cg-RX-API-DMAC7.html)
JP2025175052A5 (cg-RX-API-DMAC7.html)
JP2023071950A (ja) Rna送達のためのイオン化可能なカチオン性脂質
KR102380363B1 (ko) Rna 전달을 위한 이온성 양이온 지질
JP3189279B2 (ja) 核酸コポリマー含有医薬組成物
TWI699354B (zh) 陽離子性脂質
JP2022505234A5 (cg-RX-API-DMAC7.html)
JP2024500673A5 (cg-RX-API-DMAC7.html)
US7709449B2 (en) Nucleic acid-based compounds and methods of use thereof
ES2475065T3 (es) Aminol�pidos mejorados y métodos para la administración de ácidos nucleicos
US11904052B2 (en) Methods for ameliorating infusion reactions
ES2537568T3 (es) Nuevos fármacos para inhibición de la expresión genética
JP2024540101A5 (cg-RX-API-DMAC7.html)
JP6542662B2 (ja) オリゴヌクレオチドアナログのボロン酸結合体
AU2013270685A1 (en) Lipids for therapeutic agent delivery formulations
JP2022513111A5 (cg-RX-API-DMAC7.html)
JP7626405B2 (ja) シスチン骨格を有する新規カチオン性脂質
CA3000617A1 (en) Nucleic acid derivative having immunostimulatory activity
TW202435851A (zh) 用於治療b型肝炎之治療組合物及方法
IL294599A (en) 4’-o-methylene phosphonate nucleic acids and analogues thereof
CN120359208A (zh) 可电离脂质及其用途
JP2924179B2 (ja) グリセロール誘導体,デバイス及び医薬組成物
CA3232690A1 (en) Multi-motif dendrons and their supramolecular structures and uses thereof
KR102933360B1 (ko) 신규한 지질 화합물 및 이를 포함하는 지질 나노입자 조성물
CA2525091A1 (en) Water-soluble shps as novel alkylating agents